Stock Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Vertex to Announce First Quarter 2016 Financial Results on April 27

[Business Wire] – Vertex Pharmaceuticals Incorporated will report its first quarter 2016 financial results on Wednesday, April 27, 2016 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. Read more on this. Vertex Pharmaceuticals Incorporated (VRTX) , with a current market cap of $20.25B, started the session at $87.42. Looking at the equity, the company’s one day range is $82.05 to $87.42 with the price of the stock fluctuating between $75.90 to $143.45 over the last 52 weeks. VRTX shares are currently priced at 42.59x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -2.56x earnings multiple for the same period. Consensus earnings for the current quarter by the 19 sell-side analysts covering the stock is an estimate of $0.30 per share, which would be $0.30 worse than the year-ago quarter and a $0.10 sequential decrease. What we find to be interesting is that the full-year EPS estimate of $2.00 is a $3.11 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $439.94 Million. If realized, that would be a 217.65% increase over the year-ago quarter. More recently, Jefferies upgraded VRTX from Hold to Buy (Feb 1, 2016). Previously, Credit Suisse Initiated VRTX at to Outperform. Investors should keep in mind is that the average price target is $122.57, which is 40.21% above where the stock opened this morning. See more in (NASDAQ:VRTX) Similar Articles: Stock Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – What Vertex’s Results Mean for Corbus, ProQR, and Nivalis Market Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Vertex Receives Complete Response Letter from U.S. FDA for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older with One of 23 Residual Function Mutations Company Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2015 Financial Results